453 related articles for article (PubMed ID: 17935281)
1. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
2. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: TG-1031, Transgene SA.
Doehn C; Jocham D
Curr Opin Mol Ther; 2000 Feb; 2(1):106-11. PubMed ID: 11249647
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
[TBL] [Abstract][Full Text] [Related]
5. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
6. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
7. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Dreicer R; Stadler WM; Ahmann FR; Whiteside T; Bizouarne N; Acres B; Limacher JM; Squiban P; Pantuck A
Invest New Drugs; 2009 Aug; 27(4):379-86. PubMed ID: 18931824
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
[TBL] [Abstract][Full Text] [Related]
9. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
10. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
11. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
Sangha R; Butts C
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
[TBL] [Abstract][Full Text] [Related]
12. Emepepimut-S for non-small cell lung cancer.
Corrales-Rodriguez L; Blais N; Soulières D
Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted agents for lung cancer.
West HJ
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
15. MUC1 and breast cancer.
Apostolopoulos V; Pietersz GA; McKenzie IF
Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
[TBL] [Abstract][Full Text] [Related]
16. Leuvectin Vical Inc.
Kaushik A
Curr Opin Investig Drugs; 2001 Jul; 2(7):976-81. PubMed ID: 11757801
[TBL] [Abstract][Full Text] [Related]
17. Are vaccines making a comeback in non-small-cell lung cancer?
Nemunaitis JJ
J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
[No Abstract] [Full Text] [Related]
18. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: BLP-25, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2001 Feb; 3(1):102-5. PubMed ID: 11249725
[TBL] [Abstract][Full Text] [Related]
20. 5T4 as a target for immunotherapy in renal cell carcinoma.
Elkord E; Shablak A; Stern PL; Hawkins RE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
